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A B S T R A C T
Background
It is estimated that up to 1% of people in high-income countries suFer from a leg ulcer at some time in their life. The majority of leg ulcers
are associated with circulation problems; poor blood return in the veins causes venous ulcers (around 70% of ulcers) and poor blood
supply to the legs causes arterial ulcers (around 22% of ulcers). Treatment of arterial leg ulcers is directed towards correcting poor arterial
blood supply, for example by correcting arterial blockages (either surgically or pharmaceutically). If the blood supply has been restored,
these arterial ulcers can heal following principles of good wound-care. Dressings and topical agents make up a part of good wound-care
for arterial ulcers, but there are many products available, and it is unclear what impact these have on ulcer healing. This is the third update
of a review first published in 2003.
Objectives
To determine whether topical agents and wound dressings aFect healing in arterial ulcers. To compare healing rates and patient-centred
outcomes between wound dressings and topical agents.
Search methods
The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, Cochrane Central Register of
Controlled Trials, MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature and Allied and Complementary Medicine
databases, the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials register to 28 January
2019.
Selection criteria
Randomised controlled trials (RCTs), or controlled clinical trials (CCTs) evaluating dressings and topical agents in the treatment of arterial
leg ulcers were eligible for inclusion. We included participants with arterial leg ulcers irrespective of method of diagnosis. Trials that
included participants with mixed arterio-venous disease and diabetes were eligible for inclusion if they presented results separately for the
diFerent groups. All wound dressings and topical agents were eligible for inclusion in this review. We excluded trials which did not report
on at least one of the primary outcomes (time to healing, proportion completely healed, or change in ulcer area).
Data collection and analysis
Two review authors independently extracted information on the participants' characteristics, the interventions, and outcomes using a
standardised data extraction form. Review authors resolved any disagreements through discussion. We presented the data narratively due
to diFerences in the included trials. We used GRADE to assess the certainty of the evidence.
Dressings and topical agents for arterial leg ulcers (Review)
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Main results
Two trials met the inclusion criteria. One compared 2% ketanserin ointment in polyethylene glycol (PEG) with PEG alone, used twice a day
by 40 participants with arterial leg ulcers, for eight weeks or until healing, whichever was sooner. One compared topical application of
blood-derived concentrated growth factor (CGF) with standard dressing (polyurethane film or foam); both applied weekly for six weeks by
61 participants with non-healing ulcers (venous, diabetic arterial, neuropathic, traumatic, or vasculitic). Both trials were small, reported
results inadequately, and were of low methodological quality. Short follow-up times (six and eight weeks) meant it would be diFicult to
capture suFicient healing events to allow us to make comparisons between treatments.
One trial demonstrated accelerated wound healing in the ketanserin group compared with the control group. In the trial that compared
CGF with standard dressings, the number of participants with diabetic arterial ulcers were only reported in the CGF group (9/31), and the
number of participants with diabetic arterial ulcers and their data were not reported separately for the standard dressing group. In the
CGF group, 66.6% (6/9) of diabetic arterial ulcers showed more than a 50% decrease in ulcer size compared to 6.7% (2/30) of non-healing
ulcers treated with standard dressing. We assessed this as very-low certainty evidence due to the small number of studies and arterial ulcer
participants, inadequate reporting of methodology and data, and short follow-up period.
Only one trial reported side eFects (complications), stating that no participant experienced these during follow-up (six weeks, low-certainty
evidence). It should also be noted that ketanserin is not licensed in all countries for use in humans. Neither study reported time to ulcer
healing, patient satisfaction or quality of life.
Authors' conclusions
There is insuFicient evidence to determine whether the choice of topical agent or dressing aFects the healing of arterial leg ulcers.
P L A I N   L A N G U A G E   S U M M A R Y
Dressings and topical agents for arterial leg ulcers
What is the research question?
Does the choice of topical agents (creams or ointments) or wound dressings aFect the healing of arterial leg ulcers?
Background
People with blood circulation problems in their legs can develop leg ulcers, with adults having around a 1% chance of suFering from a leg
ulcer at some time in their life. The majority of ulcers (around 70%), result from poor blood flow in the veins and are called venous leg ulcers.
These are generally treated by compression. Arterial leg ulcers (around 22% of ulcers) occur because of poor blood supply to the legs, when
there is a block in a leg artery or narrowing of the arteries (atherosclerosis). Without treatment of the underlying poor arterial blood supply,
ulcers take a long time to heal or may even never heal. These ulcers are treated to promote healing and protect from infection, by covering
them with dressings or using topical agents, or both. A variety of types of dressings can be used, depending on whether the main intention
is to treat infection, reduce ulcer pain, or manage the fluid that can leak from these ulcers (exudate), and so promote healing.
Study characteristics and key results
We found two small studies that presented data for 49 participants with arterial leg ulcers (search conducted January 2019). The studies
also included participants with other kinds of ulcers, and it is not clear what proportion of participants were diabetic. Neither study
described the methods fully, both presented limited results for the arterial ulcer participants, and one study did not provide information
on the number of participants with an arterial ulcer in the control group. The follow-up periods (six and eight weeks) were too short to
measure healing. Therefore, the data that were available were incomplete and cannot be generalised to the greater population of people
who suFer from arterial leg ulcers.
One study randomised participants to either 2% ketanserin ointment in polyethylene glycol (PEG) or PEG alone, administered twice a day
over eight weeks. This study reported increased wound healing in the ketanserin group, when compared with the control group. It should
be noted that ketanserin is not licensed for use in humans in all countries.
The second study randomised participants to either topically-applied growth factors isolated from the participant's own blood
(concentrated growth factors (CGF)), or standard dressing; both applied weekly for six weeks. This study reported that 66.6% of CGF-treated
diabetic arterial ulcers showed more than a 50% decrease in ulcer size, compared to 6.7% of non-healing ulcers treated with standard
dressing.
Only one study mentioned side eFects, and reported that no participant experienced side eFects during follow-up (six weeks). Neither of
the two studies reported time to ulcer healing, patient satisfaction or quality of life measures.
Certainty of the evidence
Dressings and topical agents for arterial leg ulcers (Review)
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There is insuFicient evidence to determine whether the choice of topical agent or dressing aFects the healing of arterial leg ulcers. We
downgraded the overall certainty of the available evidence to 'very low' and 'low', because the studies reported their methods poorly, there
were only two studies and few participants with arterial disease, and because the studies were short and reported few results. This made
it impossible to determine whether there was any real diFerence in the number of ulcers healed between the groups.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.
Topical agents compared with control or standard dressing for arterial ulcers
Patient or population: participants with arterial ulcersa
Settings: not indicated
Intervention: topical agentb
Comparison: control or standard dressing
Anticipated absolute effects * (95% CI)Outcomes
Risk with control or standard
dressing















Time to ulcer healing Neither study reported on time to ulcer healing. - - -
Change in ulcer area
over time
(6 - 8 weeks)
Rooman 1991 reported that participants receiving ketanserin would reach 50% healing at 3.5 weeks and the
control group at 6.3 weeks.
Santoro 2018 reported wound reduction of at least 50% of surface and volume of lesion in 6/9 (66.6%) of the









(6 - 8 weeks)
Not reported by Rooman 1991.







and quality of life da-
ta
Neither study reported patient satisfaction and quality of life. - - -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CGF: concentrated growth factor; CI: confidence intervals; PEG: polyethylene glycol
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
































































































































Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
a Rooman 1991 involved 299 participants, of which, 40 had ulcers due to arterial disease. Santoro 2018 involved 61 participants. 9/31 participants in the CGF group had diabetic
arterial ulcers, but it is not clear how many arterial ulcers were in the standard dressing group.
b Rooman 1991 evaluated the use of 2% ketanserin ointment in PEG compared with a PEG alone control group. Santoro 2018 evaluated the use of topical application of CGF
compared with standard dressing.
c We downgraded from high to very low due to imprecision (very small numbers of participants with arterial ulcers); short follow up period; and concerns over risk of bias
(inadequate methods reporting and details on participants, inadequate reporting of subgroup data).
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B A C K G R O U N D
Description of the condition
Leg ulceration is a common, chronic condition that is painful and
reduces health-related quality of life. A systematic review estimated
that 0.12% to 1.1% of the adult population suFers from lower-
limb ulcers (Graham 2003). The major causes of ulceration include
venous insuFiciency (poor blood flow in the veins), arterial disease,
and diabetes. Although the majority of leg ulcers are due to venous
disease, a significant number (around 22%) of people with leg
ulcers have arterial insuFiciency. 10% to 20% of leg ulcers can
be of mixed aetiology, for example due to arterial and venous
disease, or diabetes with arterial disease (Harding 2015; SIGN 2010).
Arterial leg ulcers develop due to inadequate blood supply to the
skin. This may be caused by narrowing of the arteries to the legs
(atherosclerosis). It is essential to diFerentiate between arterial and
venous ulcers, as the mainstay of treatment for venous leg ulcers
is compression therapy (SIGN 2010; O'Meara 2012), which may lead
to skin necrosis (or potentially even to amputation) if applied to
arterial leg ulcers (Callam 1987).
Diagnosis of arterial insuFiciency, or peripheral arterial disease
(PAD), is made by taking a medical history. The most common
accompanying complaint is pain, which may occur when walking
or during exercise. When cramping pain occurs in the leg
aOer exercise, and resolves on resting, it is called intermittent
claudication. This complaint can progress until the person is
eventually in pain even at rest.
In order to assess how much blood flow there is in a leg, tests
are oOen undertaken to confirm the presence or absence of
arterial disease. Generally, the first evaluation is the ankle brachial
index (ABPI, ABI). If this test results in an ABI ratio of less than
0.7, compression treatment is inadvisable and the person will
be referred to a vascular specialist who can order further tests,
such as duplex ultrasound or arteriography (Grey 2006). The ABI
threshold generally ranges between a ratio of 0.6 and 0.7, with
some variation in the literature. The diagnosis of PAD is complicated
in people with diabetes, as neuropathy can mask symptoms and
non-compressible vessels can result in inaccurate ABI readings
(Brownrigg 2016).
The key to treatment of arterial insuFiciency is to improve the blood
supply, Therefore, surgery is oOen required in order to bypass or
clear the blockage. For a number of people this may not be possible,
due to their preference, age and general health, or due to diFuse
distal arterial disease, where the vessels to be reconstructed are
very small. Non-surgical options include good wound-care, exercise
to increase blood supply to the leg, pharmaceutical interventions,
or physical therapies such as hyperbaric oxygen. This review only
considers the use of wound dressings and topical agents in the
treatment of arterial ulcers.
Description of the intervention
Dressings are usually placed over the ulcer. Ever since Winter
1962 observed that, in pigs, an acute wound covered by an
occlusive dressing healed more rapidly than one exposed to air,
clinicians have tried to create the ideal wound-healing environment
by applying dressings that limit the loss of water vapour from
the wound. However, it is not clear whether a moist wound
environment is best for all wounds, regardless of aetiology (their
cause). For some arterial leg ulcers accompanied by dry black toes
or dry black heels, best practice recommends keeping the ulcers
dry, until the dead tissue separates naturally from the healthy
tissue. According to the British National Formulary (BNF), the main
requirements of a dressing are to keep the wound moist with
exudate (but not macerated), free of infection and excessive slough,
free of toxic chemicals or fibres, at the optimal healing temperature,
undisturbed, and at an optimal pH level (BNF 2013). In the UK,
the BNF has classified dressings into categories to aid clinicians
in selecting appropriate products. DiFerent countries may use
diFerent systems for classifying dressings and topical agents
(ointments and creams). In addition, there are a number of topical
agents which aim to change the wound environment, for example
cadexomer iodine, honey, phenytoin, silver and ketanserin. Topical
agents are oOen used in combination with dressings, and provide
an antimicrobial and antibacterial environment (SIGN 2010). Other
therapies that have been used to treat arterial ulcers include
hyperbaric oxygen, vacuum therapy and skin graOing. These are not
considered in this review.
How the intervention might work
Dressings have the ability to allow excess exudate to be removed
from the wound surface, provide a moist micro-environment,
reduce ulcer pain, act as a semipermeable membrane, be
impermeable to micro-organisms and provide thermal insulation
(BNF 2013; SIGN 2010). There is a large array of dressings, and not
all will have all of the above abilities. However, dressings should
be sterile and contaminant-free (i.e. leave no dressing material
in the wound), should not cause an allergic reaction and should
not cause trauma when removed. DiFerent topical agents also
have diFerent modes of action, and can act to reduce or prevent
infection, facilitate cleansing and debridement, or reduce platelet
aggregation in the capillaries and improve blood flow (Rooman
1991; Vanhoutte 1988).
Why it is important to do this review
Although there are many types of dressings and topical agents
available, there is currently little evidence for their eFect on the rate
of healing in arterial ulcers.
O B J E C T I V E S
To determine whether topical agents and wound dressings aFect
healing in arterial ulcers. To compare healing rates and patient-
centred outcomes between wound dressings and topical agents.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) or controlled
clinical trials (CCTs) that evaluated dressings and topical agents
in the treatment of arterial leg ulcers. Trials that used allocation
processes which are transparent before assignment, such as an
open list of random numbers, case record, day of the week,
surname and so forth, were eligible for inclusion in the review.
Types of participants
We included men and women of any age with an arterial leg ulcer,
irrespective of the method of diagnosis used. Trials that included
Dressings and topical agents for arterial leg ulcers (Review)
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participants with mixed arterio-venous disease and diabetes were
eligible for inclusion if they presented results separately for
participants with uncomplicated arterial disease (sometimes called
pure arterial disease).
Types of interventions
Interventions of interest included any dressing or topical agent
applied to arterial leg ulcers. Comparisons were against either no
dressing/topical agent, or against other dressings or local agents.
We also accepted placebo comparators, but it was not possible
to describe any comparator as a true placebo, as every local
agent will have an eFect on the rate of moisture loss from the
surface of the ulcer, and thus may potentially have an impact on
healing. We excluded studies that gave compression treatment
to all participants, as this treatment is specific to venous ulcers
and can be harmful when applied to arterial ulcers. Compression
treatments can be used safely in people with an ABI ≥ 0.8, but
people with moderate to severe arterial disease will generally have
an ABI < 0.7, and should be referred to an appropriate specialist
(SIGN 2010). We therefore excluded these kinds of trials, as they
were most likely to be studies treating primarily venous ulcers.
Trials which used concurrent interventions, for example drug
treatment or advice on exercise, were also eligible for inclusion in
the review. We recorded any concurrent interventions used.
Types of outcome measures
In order to be included in the review, a trial report had to provide at
least one of the primary outcomes (i.e. healing data).
Primary outcomes
• Time to complete ulcer healing/proportion of ulcers completely
healed in trial period: the complete healing of an ulcer is a
definitive endpoint which can be measured, and is likely to be
the outcome of greatest interest to participants and, therefore,
should be the primary outcome measure of any treatment.
• Change in ulcer area over time: although the primary outcome
of interest is the complete ulcer healing rate (defined as the
number of participants achieving complete healing), some trials
report changes in ulcer area over time. These are less valid
indicators of eFectiveness, as the rate of decrease of ulcer
area may vary during the healing process without resulting in
complete ulcer healing. In addition, expressing outcomes as
either a percentage of initial ulcer area healed, or absolute
area healed, may lead to bias, favouring either the small
or large-ulcer group where there are diFerent ulcer sizes in
the treatment groups at baseline. We used both percentage
and absolute healing rates where reported, and attempted to
describe the direction of any potential bias due to poor baseline
comparability.
Secondary outcomes
• Complications and morbidity: some of the treatments have
the potential to aFect the participant adversely. We noted
complications (e.g. discomfort, skin damage, pain, clinical
infection and amputation) wherever the trials reported these,
and compared them between interventions.
• Patient satisfaction and quality of life data: generic or specific
measures of quality of life.
We excluded studies that reported only interim outcome measures
of ulcer improvement, such as 'appearance of granulation tissue',
as the relationship between the appearance of healthy tissues (or
disappearance of unhealthy tissue) and ulcer healing is unclear.
Search methods for identification of studies
Electronic searches
The Cochrane Vascular Information Specialist conducted
systematic searches of the following databases for RCTs and
CCTs, without language, publication year or publication status
restrictions:
• the Cochrane Vascular Specialised Register via the Cochrane
Register of Studies (CRS-Web; searched on 28 January 2019);
• the Cochrane Central Register of Controlled Trials (CENTRAL)
Cochrane Register of Studies Online (CRSO; 2019, Issue 1);
• MEDLINE (Ovid MEDLINE Epub Ahead of Print, In-Process & Other
Non-Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE;
searched from 1 January 2017 to 28 January 2019);
• Embase Ovid (searched from 1 January 2017 to 28 January
2019);
• CINAHL Ebsco (Cumulative Index to Nursing and Allied Health
Literature; searched from 1 January 2017 to 28 January 2019);
• AMED Ovid (Allied and Complementary Medicine; searched from
1 January 2017 to 28 January 2019).
The Information Specialist modelled search strategies for other
databases on the search strategy designed for CENTRAL. Where
appropriate, the Information Specialist combined these with
adaptations of the highly sensitive search strategy designed by
the Cochrane Collaboration for identifying randomised controlled
trials and controlled clinical trials (as described in the Cochrane
Handbook for Systematic Reviews of Interventions Chapter 6,
Lefebvre 2011). Appendix 1 shows the search strategies for major
databases.
The Information Specialist searched the following trials registries
on 28 January 2019:




We reviewed references of relevant studies for other studies of
interest that could be included.
Data collection and analysis
Selection of studies
For the update of this review, two authors (CB and MS) initially
screened abstracts and titles using Covidence soOware. They then
carried out an independent assessment of potentially relevant
abstracts and full-text articles, in terms of their relevance and
design according to the selection criteria. We obtained full versions
of articles if, from their initial assessment, they appeared to be
relevant, and then checked these to verify whether they met the
inclusion criteria. We resolved any disagreement by discussion.
Dressings and topical agents for arterial leg ulcers (Review)
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Data extraction and management
Two review authors (CB and FP) independently extracted details
of the studies. The review authors attempted to contact the study
authors to obtain any data that were missing from reports. If we
had identified any studies published in duplicate, we would have
included them only once. For each included study, we collected the
following data:
• trial setting (country, and whether primary or secondary care);
• length of follow-up;
• number of participants (or limbs or ulcers) randomised;
• inclusion criteria;
• exclusion criteria;
• description of interventions and co-interventions;




• number and reason for withdrawals;
• source of funding;
• use of an a priori sample size/power calculation.
Assessment of risk of bias in included studies
Two review authors (CB and FP) independently evaluated
the included studies for quality, using the Cochrane tool
for assessing risk of bias (Higgins 2011a). This tool provides
judgments made on seven domains, which include randomisation
sequence generation, allocation concealment methods, blinding
of participants and personnel, blinding of outcome assessors,
incomplete outcome data, selective outcome reporting, and other
relevant biases. We evaluated each included study as low risk,
unclear risk, or high risk for each domain. We resolved any
disagreements between review authors through discussion.
Measures of treatment e:ect
We planned to conduct analysis on an intention-to-treat basis,
and therefore planned to include all randomised participants of
interest in the analysis. We planned to compile the outcomes that
were dichotomous into a meta-analysis and calculate odds ratios
(ORs) with 95% confidence intervals (CIs). For continuous data,
we planned a meta-analysis using mean diFerences (MDs) with
standard deviations (SDs) and 95% CIs.
Unit of analysis issues
The unit of analysis for this review was the individual participant.
For studies that included participants with more than one ulcer,
we planned to perform a sensitivity analysis to determine if such
studies had a large impact on the eFect size.
Dealing with missing data
Where data were missing from the included study, we attempted to
contact study authors.
Assessment of heterogeneity
A test for heterogeneity examines the null hypothesis that all
studies are evaluating the same eFect. We planned to obtain P
values comparing the test statistic with a Chi2 statistic distribution.
To help readers assess the consistency of results of studies in a
meta-analysis, Review Manager 2014 includes the I2 statistic that
describes the percentage of total variation across studies that is
due to heterogeneity rather than chance (Higgins 2003). A value of
0% indicates no observed heterogeneity, and larger values show
increasing heterogeneity.
Assessment of reporting biases
To assess reporting bias, we planned to create funnel plots for meta-
analyses containing 10 or more included studies (Sterne 2011).
As only two studies were included in this review, we could not
undertake an assessment of reporting bias.
Data synthesis
We intended to make the following comparisons:
• all dressings versus no dressing;
• all occlusive or semiocclusive dressings versus traditional
dressings (such as gauze);
• occlusive or semiocclusive dressings versus other occlusive or
semiocclusive dressings (e.g. foam dressing versus film dressing;
hydrocolloid dressing versus hydrogel dressing etc.);
• topical agents versus no topical application;
• topical agents versus placebo or control;
• topical agents versus other topical agents;
• topical agents versus dressings.
We planned to combine data for these comparisons in meta-
analyses, and to use a systematic narrative overview where
synthesis in this manner was inappropriate. We planned to use
fixed-eFect models where heterogeneity was low, but if the I2
statistic was more than 50%, we planned to use a random-eFects
model.
Subgroup analysis and investigation of heterogeneity
Trials using allocation processes which are transparent before
assignment, such as an open list of random numbers, case record,
day of the week, surname and so forth, were eligible for inclusion in
the review. We planned to undertake subgroup analysis to compare
such trials with trials that had adequate allocation concealment.
Sensitivity analysis
We planned to undertake sensitivity analysis to exclude studies that
used allocation processes which are transparent before assignment
(open list of random numbers, case record, day of the week,
surname). We planned a sensitivity analysis to remove studies that
involved participants with more than one ulcer being treated within
the study, to determine whether these studies had a large impact
on the overall eFect size. We also planned a sensitivity analysis to
exclude low-quality studies, as judged by the level of risk of bias,
to determine their impact on the overall results. Due to the limited
number of included studies, we did not carry out any sensitivity
analyses.
Summary of findings and assessment of certainty of the
evidence
We created a 'Summary of findings' table to present the main
results using the Review Manager 'Summary of findings table
wizard' (Review Manager 2014), based on methods described in
Chapter 11 of the Cochrane Handbook for Systematic Reviews of
Dressings and topical agents for arterial leg ulcers (Review)
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Interventions (Higgins 2011b). We included the outcomes: time to
complete healing, change in ulcer area over time; complications
and comorbidity; and patient satisfaction or quality of life data.
We included a narrative summary of the findings as we were
not able to carry out any data synthesis. We used the GRADE
approach to assess the certainty of the evidence for each outcome
as high, moderate, low, or very low, based on the risk of bias,
inconsistency, indirectness, imprecision, and publication bias
(Atkins 2004; Higgins 2011b). See Summary of findings for the main
comparison.
R E S U L T S
Description of studies
Results of the search
See Figure 1 for the PRISMA flow-chart.
 
Figure 1.   Study flow diagram.
 
For this update, we included one new study (Santoro 2018).
We assessed four new studies as ongoing (NCT02583958;
NCT02839226; NCT03275831; NCT03468816), and two as 'awaiting
classification' (Capoano 2017; NCT00658983). We assessed
and excluded two studies which were previously 'awaiting
classification' (Gibson 1995; Morely de Benzaquen 1990). We
excluded a further 17 studies (Augustin 2016; Barouti 2015; Castell
2016; Hanumanthappa 2012; JPRN-UMIN000033048; Meaume
2014; Meaume 2017; Mo 2015; MoFatt 2014; Morimoto 2013;
NCT01036438; NCT01449422; NCT02046226; Purcell 2017; Raposio
2015; Romanelli 2016; Woo 2012).
Included studies
Summary details of the included studies are given in the
Characteristics of included studies table.
The trial by Rooman and Janssen compared 2% ketanserin
ointment in PEG with a control group that received PEG alone,
Dressings and topical agents for arterial leg ulcers (Review)
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applied twice daily, for eight weeks (Rooman 1991). For participants
with purely arterial disease, 19 people were in the ketanserin group
and 21 people in the control (PEG alone) group. This multicentre
study recruited 299 participants with decubitus ulcers: 80 had
pressure ulcers; 134 had venous ulcers; 45 had diabetic ulcers; and
40 had arterial ulcers. The publication did not describe the method
of identifying the participants. This can have an impact on the
transferability of the results to other settings, as the characteristics
of participants recruited from a tertiary referral centre or a primary
care setting may well be diFerent, e.g. duration of ulceration,
severity of underlying pathology. The trial did not report its
inclusion or exclusion criteria, or the degree of arterial impairment
for either group. The only outcome that the trial reported for the
arterial leg ulcers subgroup was wound area as a function of time,
and we could not determine time to 50% healing from the graph of
results.
Santoro 2018 included 61 participants with non-healing ulcers
(31 in CGF group and 30 in the standard dressing group). These
were of mixed aetiology, including venous ulcers, arterial diabetic
ulcers, neuropathic ulcers, traumatic ulcers and vasculitic ulcers.
The trial compared topical application of concentrated growth
factors CGF with application of a standard dressing of polyurethane
film or foam, both applied weekly for six weeks. The trial reported
numbers of participants with arterial diabetic ulcers in the CGF
group, but we could not determine the number of arterial diabetic
ulcers in the standard dressing group. CGF was an autologous
preparation obtained from the participants' own blood, believed
to be rich in platelet-derived growth factors, such as transforming
growth factor beta1 and 2, fibroblast growth factor, vascular
endothelial growth factor, insulin-like growth factor and stem
cells. The trialists used MOWA graphics soOware (MObile Wound
Analyzer) to calculate ulcer size.
Excluded studies
Summary details of excluded studies are given in the
Characteristics of excluded studies table.
For this update, we excluded an additional 19 studies (20
reports) (Augustin 2016; Barouti 2015; Castell 2016; Gibson 1995;
Hanumanthappa 2012; JPRN-UMIN000033048; Meaume 2014;
Meaume 2017; Mo 2015; MoFatt 2014; Morely de Benzaquen
1990; Morimoto 2013; NCT01036438; NCT01449422; NCT02046226;
Purcell 2017; Raposio 2015; Romanelli 2016; Woo 2012).
This includes two studies which were previously 'awaiting
classification', but which we have now excluded as we were unable
to obtain the full texts for these (Gibson 1995; Morely de Benzaquen
1990).
This made a total of 82 excluded studies. The main reason for
exclusion (32 studies) was a lack of outcome data presented
by ulcer aetiology (Armstrong 1996; Augustin 2016; Bale 1998;
Barouti 2015; Castell 2016; Daltrey 1981; Fumal 2002; Harding 2001;
Janssen 1989; Kalis 1993; Krupski 1991; Meaume 2014; Meaume
2017; Mian 1991; Milward 1991; Mo 2015; Morimoto 2013; Motta
2004; Purcell 2017; Raposio 2015; Romanelli 2016; Sibbald 2011;
Steed 1991; Svedman 1983; Tarvainen 1988; Thomas 1989; Vin 1997;
Vuerstaek 2006; Woo 2012; Wagner 1990; Weed 2004; Zykova 2014).
We could have included the majority of these studies if the authors
had given subgroup data by ulcer aetiology. We excluded 23 studies
because the publications did not provide enough information for
us to determine whether arterial ulcers were included (Bassetti
1970; Casoni 2001; Chaloner 1992; Falabella 1998; Gago Fornells
2002; Hanumanthappa 2012; Ishibashi 1990; Jorgensen 2003;
Kordestani 2008; Larsen 1997; Leaper 1986; Luongo 2003; MoFatt
2014; Moss 1984; Munter 2006; NCT01036438; NCT01449422; Nyfors
1982; Pendse 1993; Polignano 2001; Quatresooz 2006; Serra 2005;
Wollina 1997). Seventeen studies did not report outcomes that
were within the scope of the review, i.e. healing data (Altman
1976; Armstrong 1997; Banks 1997; Boxer 1969; Da Costa 1997;
Gibson 1986; Holm 1990; Holst 1998; Jansen 2009; Johnson 1992;
Jørgensen 2009; JPRN-UMIN000033048; Knighton 1988; Knighton
1991; Stromberg 1984; Varelias 2006; Wu 1996. The remaining 10
studies were excluded for other reasons: Hartman 2002 was not an
RCT; one study included identical interventions in the comparison
groups (Gamborg Nielson 1989); one study included only a single
participant with an arterial ulcer, who did not have a comparator
(Huber 1991); one study included a treatment that is no longer
available (Leaper 1991); one study applied the treatment to the skin
around the ulcer and not the ulcer directly (Neander 2004); and
one study excluded participants with "deep arterial disease" (Senet
2011). We could not obtain a copy of the study by Schmutz 1997,
but a previous Cochrane Review 'Dressings for healing venous leg
ulcers' excluded it for the following reason: "Report of design of
trial no results given. Author contacted but no reply" (Palfreyman
2006). We were also unable to obtain full copies of Gibson 1995
or Morely de Benzaquen 1990. Finally, although NCT02046226 met
the inclusion criteria, the study was terminated due to lack of
recruitment.
Ongoing studies
Four new ongoing studies were identified (NCT02583958;
NCT02839226; NCT03275831; NCT03468816). See Characteristics of
ongoing studies for further details.
Studies awaiting classification
We assessed two studies as 'awaiting classification' (Capoano
2017; NCT00658983). See Characteristics of studies awaiting
classification for further details.
Risk of bias in included studies
A graphical description of the included studies' risk of bias can be
seen in Figure 2 and Figure 3.
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Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Allocation
Neither Rooman 1991 nor Santoro 2018 described the
randomisation method within the text. It is unclear how people
were allocated to the two groups, whether allocation sequence was
randomly generated or if allocation was concealed, leading to a
rating of 'unclear' for selection bias.
Blinding
Rooman 1991 described their trial as double-blind, using a
placebo control, but did not describe the steps taken to ensure
that clinicians and participants were unaware of the treatment
(ketanserin or control). Rooman 1991 did not report how successful
this blinding was, nor whether the people assessing the wound,
by taking wound tracings, were blinded. Santoro 2018 did not
mention blinding of participants, personnel or outcome assessors.
We therefore rated both performance and detection bias for both
studies as 'unclear'.
Incomplete outcome data
We rated attrition bias as 'low' in the Rooman 1991 study, as all
participants appeared in the analyses. The trialists did not discuss
any dropouts or loss-to-follow-up. As Santoro 2018 only reported
the arterial ulcer data for the intervention group and not the control
group, we rated attrition bias as 'unclear' for this study.
Selective reporting
The studies reported on all outcomes that were discussed in the
publications' methods sections, so we gave both studies a 'low'
rating for reporting bias. These outcomes included granulation
tissue, degree of re-epithelialisation, wound surface area and a
global assessment of the evolution of the ulcer in Rooman 1991.
Santoro 2018 reported wound size and side eFects.
Other potential sources of bias
We gave Rooman 1991 an 'unclear' rating for other sources of bias,
as the trial did not perform an a priori power calculation, and with
low numbers of participants with arterial ulcers (40 participants
in total; 19 people receiving treatment and 21 people receiving
control), the results may not be powered to answer the study
questions of this review. We also gave Santoro 2018 a rating of
'unclear' risk of other bias, as it was a conference abstract (not peer
reviewed), it is not clear if the use of the MOWA graphics soOware is
validated, and the study included a small number of arterial ulcer
participants (exact number unclear).
E:ects of interventions
See: Summary of findings for the main comparison
Primary outcomes
Time to complete ulcer healing/proportion of ulcers completely
healed in trial period
Not reported.
Change in ulcer area over time
The only outcome that the Rooman 1991 study reported by
ulcer aetiology was wound area as a function of time, and they
presented this data in a graph. Rooman 1991 predicted that
participants receiving ketanserin would reach 50% healing at 3.5
weeks and those in the control group at 6.3 weeks, meaning that the
ketanserin-treated participants healed nearly twice as fast as the
control-treated participants ("1.8 fold"; Rooman 1991), reported by
Rooman 1991 to be statistically significant at P < 0.01. It should be
noted that the average ulcer size at the start of the trial was larger in
the control group compared with the ketanserin group, which could
bias the results, even though the wound area was a percentage of
the initial size (ketanserin 9.41 cm2; control 11.03 cm2).
Santoro 2018 used the primary outcome of wound reduction of at
least 50% surface and volume of lesion aOer six-weeks' treatment.
They reported that this was achieved in 19/31 (61.3%) of the CGF
group, compared to 2/30 (6.7%) of the standard dressing control
group. In the CGF group, nine participants had arterial diabetic
ulcers, and six of the nine (66.6%) showed at least a 50% reduction
in ulcer size. The study did not report subgroup data for diabetic
arterial ulcers within the standard dressing group, so it was not
possible to make a direct comparison with the appropriate control
group.
We used the GRADE approach to assess the certainty of evidence
for this outcome, and rated it as very low-certainty evidence (see
Summary of findings for the main comparison).
Secondary outcomes
Complications and morbidity
Not reported by Rooman 1991. Santoro 2018 reported that no
participant presented with side eFects during follow-up.
We used the GRADE approach to assess the certainty of evidence of
this outcome, and rated it as low-certainty evidence (see Summary
of findings for the main comparison).
Patient satisfaction and quality of life data
Not reported.
D I S C U S S I O N
Summary of main results
Rooman 1991 evaluated the use of a 2% ketanserin ointment in
polyethylene glycol (PEG), compared with a PEG alone control
group. There were a total of 299 participants in the trial, of whom
only 40 people had ulcers due to arterial disease. We were able to
evaluate outcomes from the study as it gave a subgroup analysis
of the 40 arterial ulcer participants separately. The only outcome
that the trial reported by ulcer aetiology was wound area as a
function of time, which demonstrated that ketanserin ointment
accelerated the healing of arterial ulcers (nearly twice as fast as
the PEG alone control group). Santoro 2018 evaluated the use
of an autologous preparation from the participants' own blood,
which contained concentrated growth factors (CGF), compared
with standard dressing (polyurethane film or foam), both applied
weekly for six weeks. The trialists presented data separately for
diabetic arterial ulcers, but only for the treatment group, so we were
unable to compare with the appropriate control group. Rooman
1991 did not report adverse eFects, and Santoro 2018 reported that
no participants presented with side eFects.
Whilst the results of the included trials might appear positive,
the inadequate reporting of results, in combination with the
lack of reporting of methods used in the trial (e.g. method of
Dressings and topical agents for arterial leg ulcers (Review)
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allocation), means that we cannot confidently conclude that there
is accelerated healing due to either ketanserin 2% ointment when
compared with PEG alone, or due to CGF compared with standard
dressing. In addition, the follow-up times were too short (at six
and eight weeks) to be able to capture suFicient healing events
to allow us to make comparisons. The lack of clearly stated
inclusion and exclusion criteria in the included trials means that
the method of identifying arterial ulcers was unclear, which reduces
the generalisability of the results. Also, it should be noted that
ketanserin is not licensed in all countries for use in humans. We
assessed the certainty of the evidence to be very low for ulcer
healing, and low for complications and morbidity. Neither of the
trials reported time to ulcer healing, patient satisfaction or quality
of life.
Overall completeness and applicability of evidence
Both included studies were of relatively low methodological
quality, gave limited explanation of methods, and oFered very
little outcome data for the arterial ulcer subgroup. There were few
participants, and the follow-up time was inadequate. In addition,
we were unable to extract data specific to the diabetic arterial
ulcer standard dressing (control) group. Therefore, the data that
were available were incomplete, and cannot be generalised to the
greater population of people who suFer from arterial leg ulcers.
There are many underlying reasons why such limited high-quality
evidence is available for this topic. Venous ulcers are far more
prevalent than arterial ulcers, so gaining enough participants for
a trial of only arterial ulcers is much more diFicult. Trials in
wound care will always be faced with participants who vary in
a large number of respects, for example the size and duration
of the ulcer, the degree of arterial impairment, and concurrent
treatments such as wound cleansing, exercise, nutrition and other
self-care activities. This variability in participant characteristics
means that an investigation examining which treatment option
to use needs to employ a study design that takes into account
the diFerences between participants. A randomised controlled trial
(RCT) is the most powerful study design, but designing a double-
blind RCT in dressing eFicacy is challenging due to various issues.
These challenges include: the diFiculty of controlling the variables
associated with comorbidities; calculating sample sizes to achieve
statistical significance; recruiting enough participants; challenges
with validating infection, inflammation and wound sizes; and
challenges with validating subjective assessments, such as comfort
and user-friendliness. In the UK, dressings are considered 'medical
devices'; they are CE marked (Conformité Européenne or European
Conformity), therefore safe to be used in the context for which
they have been designed, but they are not submitted to rigorous
trial processes like pharmaceutical products (i.e. drugs). There is
therefore little incentive to fund large trials. This lack of research is
hindered by limited legislation, as manufacturers are not required
by law to provide evidence of eFicacy (Madden 2012). Therefore,
simply recommending further RCTs or controlled clinical trials
(CCTs) may not be helpful. We suggest instead that alternative
methodologies are explored to provide some guidance to clinicians
on the best way to care for arterial leg ulcers.
Quality of the evidence
Using GRADE criteria, we rated the certainty of evidence as low
to very low, due to small numbers of relevant studies, inadequate
reporting of the results, and too short a follow-up time (six or
eight weeks) to be able to capture suFicient healing events to
make comparisons. As discussed above, the trials presented very
limited outcome data for the arterial ulcer subgroup. We deemed
the methodological quality to be low, because we gave the majority
of bias domains an 'unclear' rating due to inadequate reporting. We
only rated two of the seven domains as low risk for the Rooman
1991 study: attrition bias and reporting bias. We only rated one
domain as low risk in the Santoro 2018 study (reporting bias).
The study did not discuss randomisation methods and allocation
concealment, or give any indication of blinding methods. The trials
did not identify outcome assessors as blinded, and the low number
of participants could bias the results. The trials did not report
essential information about how and where the participants were
recruited, neither did they present full inclusion and exclusion
criteria.
Potential biases in the review process
The authors took precautions to prevent reviewer biases in the
review process, including independent, duplicate inclusion and
exclusion of identified studies, risk of bias assessments and data
extraction. For this particular review, a concern with bias lies
in the fact that many studies did not indicate whether their
included participants had arterial disease, or did not indicate
any diagnostic criteria that would allow the readers to determine
arterial disease. This could have led us to exclude studies that did,
in fact, meet the inclusion criteria. To combat this issue, the review
authors assessed studies carefully and discussed any uncertainties
amongst themselves.
Agreements and disagreements with other studies or
reviews
We have not identified any other systematic reviews that evaluated
the eFect of diFerent dressings or topical agents on the healing of
arterial leg ulcers.
A Cochrane Review, published in 2006, evaluated the eFects of
diFerent dressings on venous leg ulcers when applied under
compression bandages (Palfreyman 2006). Although the review
included a total of 42 studies, the authors could not conclude
that any one type of dressing was superior to another. This review
has since been split into four separate reviews of specific dressing
types, to determine any eFect of alginate dressings (O'Meara
2013a), foam dressings (O'Meara 2013b), hydrocolloid dressings
(Ribeiro 2014), and hydrogel dressings (Ribeiro 2013). The foam
and alginate-dressing reviews still found no diFerence between
the eFectiveness of diFerent dressing type on ulcer healing.The
hydrocolloid and hydrogel reviews are still in preparation, and are
currently only published as protocols. While we cannot draw any
conclusions about arterial ulcers from these reviews, they provide
relevant information on the topic of dressings for ulcers, as well as
the current state of knowledge and research.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
There is insuFicient evidence to determine whether the choice of
topical agent or dressing aFects the healing of arterial leg ulcers.
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Implications for research
This review has identified a lack of evidence to support or reject
the use of dressings or topical agents in the healing of arterial leg
ulcers. As indicated in the Overall completeness and applicability
of evidence section, there are many issues that inhibit the design
and conduct of RCTs for the investigation of dressings and topical
agents for ulcers. To ensure future RCTs or CCTs are applicable
to the variety of people with arterial leg ulcers, and therefore
useful to clinicians, they must balance the variables arising from
comorbidities, and address the challenges relating to recruitment
and validation of outcome measurements.
Nevertheless, there is a requirement for the following studies in the
healing of arterial leg ulcers:
• comparison between various modern dressings;
• comparison between wound dressings alone versus topical
agents applied underneath wound dressings.
These studies should have clear inclusion and exclusion criteria,
and suFiciently long follow-up to determine dressing eFectiveness.
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Characteristics of included studies [ordered by study ID]
 
Methods Trial design: "double-blind, placebo controlled study"
Setting: Belgium
Primary or secondary care: not indicated
Intention-to-treat: not indicated
Funding source: not indicated
A priori sample size calculation: not indicated
Participants Number of participants: a total of 299 participants with decubitus ulcers in study, but only 40 with arte-
rial disease (n = 19 ketanserin; n = 21 control); only the 40 with arterial disease are of interest in this re-
view.
Age (entire study population): ketanserin 70.2 years; control 96.6 years
Gender (entire study population): 89 males, 208 females, 2 not specified (ketanserin 44 males,106 fe-
males; control 45 males,102 females, 2 not specified)
Ulcer size (entire study population): ketanserin 9.41 cm2; control 11.03 cm2
Ulcer age (entire study population): ketanserin 412 days; control 480 days
Inclusion criteria: not indicated, it was not clear how the diagnosis of 'arterial ulceration' was made
Exclusion criteria: not indicated
Withdrawals: not indicated
Interventions Treatment: 2% ketanserin ointment in PEG, applied twice daily
Control: PEG ointment (unclear how many times applied daily)
Follow-up: 8 weeks or until healing, whichever was sooner
Outcomes Relative wound area as a function of time
Other outcomes were reported, but trial authors did not differentiate the results by ulcer aetiology
Notes No additional surgical interventions were mentioned
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Unclear risk "Double-blind, placebo controlled", but no description of methods used to en-
sure blinding.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk All participants appeared in analyses; no discussion of dropouts.
Selective reporting (re-
porting bias)
Low risk All identified outcomes reported on.





Methods Trial design: randomised
Setting: Italy
Primary or secondary care: not indicated
Intention-to-treat: not indicated
Funding source: not indicated
A priori sample size calculation: not indicated
Participants Number of participants: 61 participants with non-healing ulcers (31 in CGF group and 30 in the stan-
dard dressing group)
Age (entire study population): mean age 69.3 years
Gender (entire study population): 50.8% male
Ulcer size (entire study population): not indicated
Ulcer age (entire study population): not indicated
Inclusion criteria: participants with non-healing ulcers (venous, arterial diabetic, neuropathic, traumat-
ic, vasculitic)
Exclusion criteria: not indicated
Withdrawals: not indicated
Interventions Treatment: topical application of CGF weekly
Santoro 2018 
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Control: application of polyurethane film or foam weekly (standard dressing)
Follow-up: 6 weeks
Outcomes Primary endpoint: reduction of at least 50% of surface and volume of lesions after 6 weeks treatment
Side effects
Notes No additional surgical interventions were mentioned
Data taken from conference abstract which indicates that a larger study is underway, although no de-
tails of this detected
Low number of participants with arterial ulcers (9 in treatment group; unclear number in control)
Authors contacted to request further details 31 May 2019 (no response received)
No details on funding provided
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details on randomisation methods provided in abstract.
Allocation concealment
(selection bias)





Unclear risk No details on blinding participants or personnel mentioned in abstract.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Arterial ulcer data available for CGF group only not standard dressing group.
Overall CGF and standard dressing data presented.
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported.
Other bias Unclear risk Wound size measured by Mobile Wound Analyser. It is not clear if this is vali-
dated.
Data presented as conference abstract only.
Low number of participants with arterial ulcers (9 in treatment group; unclear
number in control).
Santoro 2018  (Continued)
CGF: concentrated growth factor
PEG: polyethylene glycol
 
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Altman 1976 Healing data not reported.
Armstrong 1996 Outcome data not presented by ulcer aetiology.
Armstrong 1997 Healing data not reported for the two people with arterial ulcers.
Augustin 2016 Outcome data not presented by ulcer aetiology.
Bale 1998 Outcome data not presented by ulcer aetiology.
Banks 1997 Healing data not reported for the two people with arterial ulcers.
Barouti 2015 Outcome data not presented by ulcer aetiology.
Bassetti 1970 Not enough information given to determine ulcer aetiology.
Boxer 1969 Healing data not reported.
Casoni 2001 Not enough information given to determine ulcer aetiology; excluded severe peripheral atheroscle-
rotic disease.
Castell 2016 Outcome data not presented by ulcer aetiology.
Chaloner 1992 Not enough information given to determine ulcer aetiology; subjective outcome measures not
within scope of review.
Da Costa 1997 Healing data not reported.
Daltrey 1981 Outcome data not presented by ulcer aetiology.
Falabella 1998 Not enough information given to determine ulcer aetiology.
Fumal 2002 Arterial ulcers were included (along with neurological disorder-related, diabetes-related and drug
intake-related) but outcomes were not given by ulcer aetiology.
Gago Fornells 2002 Not enough information given to determine ulcer aetiology; outcome of maceration reduction not
within scope of review.
Gamborg Nielson 1989 Two groups had identical treatments.
Gibson 1986 No data on healing presented.
Gibson 1995 This study was previously awaiting classification, but we have been unable to obtain a full-text
copy.
Hanumanthappa 2012 Not enough information given to determine ulcer aetiology.
Harding 2001 Although 8% of the participants had arterial ulcers, the outcome data were not presented by ulcer
aetiology.
Hartman 2002 This study was included in the previous version of the review, but upon further investigation the
study does not fit either an RCT or CCT study design, as the control group is not adequate.
Holm 1990 No data on healing presented.
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Study Reason for exclusion
Holst 1998 No data on healing presented.
Huber 1991 Only one person with an arterial ulcer; no comparator.
Ishibashi 1990 Not enough information given to determine ulcer aetiology, only described as 'leg ulcer'.
Jansen 2009 Outcome of wound pain not within scope of review.
Janssen 1989 Outcome data not presented by ulcer aetiology.
Johnson 1992 Outcome of wound pain not within scope of review.
Jorgensen 2003 Not enough information given to determine ulcer aetiology.
JPRN-UMIN000033048 Outcome of bacterial load is not within the scope of this review.
Jørgensen 2009 Outcome of wound pain and intervention comparison with local best practice not within the scope
of the review.
Kalis 1993 Includes ulcers of mixed aetiology and does not give outcome data by aetiology.
Knighton 1988 No data on healing presented.
Knighton 1991 No data on healing presented.
Kordestani 2008 Not enough information given to determine ulcer aetiology, only described as 'leg ulcer'.
Krupski 1991 Outcome data not presented by ulcer aetiology.
Larsen 1997 Not enough information given to determine ulcer aetiology, and subjective performance outcomes
not within scope of review.
Leaper 1986 Described as ulcers of 'mixed aetiology' with not enough information given to determine specific
aetiology.
Leaper 1991 The treatment Sherisorb is no longer available.
Luongo 2003 Not enough information given to determine ulcer aetiology.
Meaume 2014 Outcome data not presented by ulcer aetiology.
Meaume 2017 Outcome data not presented by ulcer aetiology.
Mian 1991 Outcome data not presented by ulcer aetiology.
Milward 1991 Outcome data not presented by ulcer aetiology.
Mo 2015 Outcome data not presented by ulcer aetiology.
Moffatt 2014 Not enough information given to determine ulcer aetiology, but compression used so most likely
venous.
Morely de Benzaquen 1990 This study was previously awaiting classification, but we have been unable to obtain a full text
copy.
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Study Reason for exclusion
Morimoto 2013 Outcome data not presented by ulcer aetiology.
Moss 1984 Not enough information given to determine ulcer aetiology; "Forty-two outpatients with chronic
leg ulcers, mostly presumed to be venous...".
Motta 2004 Outcomes not given by aetiology; unclear if arterial ulcers were included; outcomes of bacterial
load not within scope of our review.
Munter 2006 Not enough information to determine if arterial only leg ulcers were included; dressing compared
with local best practice not within scope of review.
NCT01036438 Not enough information given to determine ulcer aetiology, but compression used so most likely
venous.
NCT01449422 Not enough information given to determine ulcer aetiology, but compression used so most likely
venous.
NCT02046226 Meets inclusion criteria, but terminated due to lack of recruitment (seven recruited participants did
not complete study).
Neander 2004 Intervention was applied to skin around ulcer, not ulcer.
Nyfors 1982 Not enough information given to determine ulcer aetiology; excluded severe peripheral atheroscle-
rotic disease.
Pendse 1993 Not enough information given to determine ulcer aetiology.
Polignano 2001 Not enough information given to determine ulcer aetiology; used compression bandages; out-
comes of angiogenesis not within scope of review.
Purcell 2017 Outcome data not presented by ulcer aetiology.
Quatresooz 2006 Not enough information given to determine ulcer aetiology.
Raposio 2015 Outcome data not presented by ulcer aetiology.
Romanelli 2016 Outcome data not presented by ulcer aetiology.
Schmutz 1997 Unable to obtain study paper. Excluded from Cochrane review: Dressing for healing venous leg ul-
cers, "Report of design of trial no results given. Author contacted but no reply" (Palfreyman 2006).
Senet 2011 Excluded participants with "deep arterial disease".
Serra 2005 Not enough information given to determine ulcer aetiology, only described as 'vascular ulcers'.
Sibbald 2011 Outcome data not presented by ulcer aetiology.
Steed 1991 Outcome data not presented by ulcer aetiology.
Stromberg 1984 Outcomes not within scope of review; data presented on 'successes' which included 'appearance
of granulation tissue' or 'reduction in area'.
Svedman 1983 Although arterial ulcers were included, outcome data not presented by ulcer aetiology.
Tarvainen 1988 Outcome data not presented by ulcer aetiology; included compression bandages.
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Study Reason for exclusion
Thomas 1989 Outcome data not presented by ulcer aetiology, also it is unclear if participants with arterial dis-
ease did not have mixed venous/arterial disease.
Varelias 2006 Outcomes not within scope of review: immunohistochemical analysis for matrix metallopro-
teinase-2, -9 and tissue inhibitor of matrix metalloproteinase-2 expression.
Vin 1997 Outcome data not presented by ulcer aetiology.
Vuerstaek 2006 Outcome data not presented by ulcer aetiology.
Wagner 1990 Outcome data not presented by ulcer aetiology; outcomes not within scope of review.
Weed 2004 Outcome data not presented by ulcer aetiology.
Wollina 1997 Not enough information given to determine ulcer aetiology.
Woo 2012 Outcome data not presented by ulcer aetiology.
Wu 1996 No data on healing
Zykova 2014 Outcome data not presented by ulcer aetiology.
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Trial design: unclear
Setting: Italy
Primary or secondary care: secondary
Funding source: not mentioned
Participants People (n = 100) with ulcers of the legs
Interventions 1) 50 participants treated with conventional therapies;
2) 50 participants treated with autologous leuco-platelet concentrate (LPC) and Hyalofill-F, a par-
tial benzyl ester derivative of hyaluronan, as a scaffold
Outcomes Area of lesion
Limb salvage
Neovascularisation
Notes Unclear if study was randomised or if all participants had arterial ulcers




Methods Trial design: RCT
NCT00658983 
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Setting: unclear
Primary or secondary care: unclear
Funding source: Medtronic, Johnson & Johnson
Participants Chronic lower leg ulcer
Interventions Autologous platelet enriched gel
Metalloproteinase inhibitor
Outcomes Wound healing
Notes Unclear if participants include arterial ulcers
Additional information requested from contact investigator 30 May 2019
NCT00658983  (Continued)
LPC: leuco-platelet concentrate
RCT: randomised controlled trial
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Assessment of efficacy and safety for a new wound dressing URGO 310 3166 in the local treatment
of venous or mixed leg ulcers: a European RCT
Methods Trial design: RCT
Setting: France
Primary or secondary care: unclear
Funding source: Laboratoires URGO
Participants People with venous or mixed leg ulcers
Interventions Intervention: URGO 310 3166 dressing
Comparison: Aquacel Extra hydrofibre dressing
Outcomes Relative regression of wound surface area
Percentage of debrided wounds
Adverse events
QoL
Starting date October 2014
Contact information Principal investigator: Sylvie Meaume, MD; Hospital Rothschild, Paris, France
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Trial name or title Safety and efficacy of topical AR/101 compared with placebo, in accelerating granulation tissue for-
mation of hard-to-heal wounds
Methods Trial design: RCT
Setting: Israel
Primary or secondary care: unclear
Funding source: Arava Bio Tech Ltd.
Participants People with hard-to-heal wound(s) of different etiologies including arterial ulcers, diabetic ulcers
and venous ulcers, of at least 3 months duration
Interventions People with wounds of ≥ 5 cm2 and ≤ 100 cm2 of at least 3 months duration that fail to respond to
treatment with SoC during the screening run-in phase will be enrolled into the study. Eligible par-
ticipants with wounds will be randomised and treated topically with AR/101+ SoC or placebo + SoC
once daily for up to 14 days.
Outcomes Comparison of the formation of new granulation tissue, according to a Granulation Score
Percentage of participants ready for skin grafting or healing by secondary intention
Per cent of participant responders of ≥ 75% granulation tissue during two weeks of treatment
Mean time to response (≥ 75% of granulation tissue) during treatment
Starting date August 2016
Contact information Sourasky Medical Center, Tel Aviv, Israel, 96105
Contact: Eyal Gur, MD; Tamar Tennenbaum, MD




Trial name or title A pilot study to investigate the efficacy of PluroGel in healing venous and mixed aetiology leg ulcers
Methods Trial design: RCT
Setting: UK
Primary or secondary care: unclear
Funding source: Medline Industries
Participants People with venous and mixed aetiology leg ulcers
Interventions Participants will be randomised at week 2 to receive either topical PluroGel or Intrasite gel (an al-
ternative topical hydrogel product)
Outcomes Change in wound size
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Starting date 8 January 2018
Contact information Aneurin Bevan University Health Board, Newport, South Wales, United Kingdom, NP20 4SZ
CardiF & Vale University Health Board, CardiF, Wales, United Kingdom, CF14 4XN






Trial name or title Wound dressing with moisture sensor
Methods Trial design: RCT
Setting: Sweden
Primary or secondary care: unclear
Funding source: Vårdcentralen Åby
Participants People with leg ulcers
Interventions Six participants will be recruited in the study and two different sensors will be compared in a cross-




Starting date 1 April 2018
Contact information Contact: MD Berglind
Hudkliniken Recruiting
Linköping, Region Östergötland, Sweden
Notes Status: recruiting
NCT03468816 
QoL: quality of life
RCT: randomised controlled trial
SoC: standard of care
 
 
A P P E N D I C E S
Appendix 1. Database search strategies
 
Source Search strategy Hits retrieved
CENTRAL via CRSO #1 MESH DESCRIPTOR Leg Ulcer EXPLODE TREES 1 1658 1557
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#2 MESH DESCRIPTOR Skin Ulcer EXPLODE ALL TREES 2405
#3 ((arter* or foot or leg or lower or mixed) adj3 ulcer*):TI,AB,KY 2677
#4 #1 OR #2 OR #3 3756
#5 MESH DESCRIPTOR Biological Dressings EXPLODE ALL TREES 82
#6 MESH DESCRIPTOR Occlusive Dressings EXPLODE ALL TREES 449
#7 MESH DESCRIPTOR HYDROGELS EXPLODE ALL TREES 305
#8 MESH DESCRIPTOR ALGINATES EXPLODE ALL TREES 232
#9 dressing*:TI,AB,KY 4199
#10 (ActivHeal or Allevyn or Avazorb or Biatain or Copa or LyoFoam or PermaFoam
or PolyMem or Suprasorb or Tegaderm or Tielle or Transobent or Trufoam or Urgo-
Cell):TI,AB,KY 244
#11 (hydrocolloid* or alginate* or hydrogel*):TI,AB,KY 2114
#12 (foam or bead or film*):TI,AB,KY 5673
#13 (tulle or gauze):TI,AB,KY 825
#14 (non adj2 adher*):TI,AB,KY 909
#15 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR
#14 14998
#16 MESH DESCRIPTOR Administration, Topical EXPLODE ALL TREES 14404
#17 MESH DESCRIPTOR Anti-Infective Agents, Local EXPLODE ALL TREES 8227
#18 MESH DESCRIPTOR Anti-Bacterial Agents EXPLODE ALL TREES 27517
#19 MESH DESCRIPTOR Anti-Inflammatory Agents EXPLODE ALL TREES 41974
#20 MESH DESCRIPTOR GLUCOCORTICOIDS EXPLODE ALL TREES 16978
#21 MESH DESCRIPTOR ESTROGENS EXPLODE ALL TREES 7217
#22 MESH DESCRIPTOR ENZYMES EXPLODE ALL TREES 28651
#23 MESH DESCRIPTOR Growth Substances EXPLODE ALL TREES 25458
#24 MESH DESCRIPTOR COLLAGEN EXPLODE ALL TREES 2294
#25 #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 129058
#26 #16 AND #25 5837
#27 (topical adj2 (steroid* or corticosteroid* or glucocorticoid*)):TI,AB,KY 1909
#28 (topical adj2 (oestrogen or estrogen)):TI,AB,KY 42
#29 (topical adj2 enzym*):TI,AB,KY 11
#30 (topical adj2 growth factor*):TI,AB,KY 31
#31 (topical adj2 collagen):TI,AB,KY 39
#32 (topical adj2 silver):TI,AB,KY 47
#33 (topical adj3 (agent* or preparation* or therap* or treatment*)):TI,AB,KY 7477
#34 MESH DESCRIPTOR OINTMENTS EXPLODE ALL TREES 1788
  (Continued)
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#35 MESH DESCRIPTOR HONEY EXPLODE ALL TREES 136
#36 honey:TI,AB,KY 486
#37 (ointment* or lotion* or cream*):TI,AB,KY 10198
#38 #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37
17152
#39 #15 OR #26 OR #38 33816
#40 #4 AND #39 3756
#41 01/01/2014 TO 28/01/2019:CD 579835
#42 #40 AND #41 1557
Clinicaltrials.gov Leg Ulcer OR Skin Ulcer OR arterial leg ulcers OR foot ulcer OR mixed ulcer | dressing
OR dressings OR hydrogel OR alginates OR Anti-Infective Agents OR Anti-Bacterial
Agents OR Anti-Inflammatory Agents OR GLUCOCORTICOIDS OR ESTROGENS OR EN-
ZYMES OR Growth Substances OR COLLAGEN
157
ICTRP Search Portal Leg Ulcer OR Skin Ulcer OR arterial leg ulcers OR foot ulcer OR mixed ulcer | dressing
OR dressings OR hydrogel OR alginates OR Anti-Infective Agents OR Anti-Bacterial
Agents OR Anti-Inflammatory Agents OR GLUCOCORTICOIDS OR ESTROGENS OR EN-




Ahead of Print, In-





2017, 2018 and 2019
only
1 exp Leg Ulcer/
2 exp Skin Ulcer/
3 ((arter* or foot or leg or lower or mixed) adj3 ulcer*).ti,ab.
4 or/1-3
5 exp Biological Dressings/




10 (ActivHeal or Allevyn or Avazorb or Biatain or Copa or LyoFoam or PermaFoam or
PolyMem or Suprasorb or Tegaderm or Tielle or Transobent or Trufoam or UrgoCel-
l).ti,ab.
11 (hydrocolloid* or alginate* or hydrogel*).ti,ab.
12 (foam or bead or film*).ti,ab.
13 (tulle or gauze).ti,ab.
14 (non adj2 adher*).ti,ab.
15 or/1-14
16 exp Administration, Topical/
17 exp Anti-Infective Agents, Local/
18 exp Anti-Bacterial Agents/
19 exp Anti-Inflammatory Agents/
1160
  (Continued)
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23 exp Growth Substances/
24 exp COLLAGEN/
25 or/17-24
26 16 and 25
27 (topical adj2 (steroid* or corticosteroid* or glucocorticoid*)).ti,ab.
28 (topical adj2 (oestrogen or estrogen)).ti,ab.
29 (topical adj2 enzym*).ti,ab.
30 (topical adj2 growth factor*).ti,ab.
31 (topical adj2 collagen).ti,ab.
32 (topical adj2 silver).ti,ab.




37 (ointment* or lotion* or cream*).ti,ab.
38 or/27-37
39 15 or 26 or 38
40 4 and 39
41 randomized controlled trial.pt.








50 exp animals/ not humans.sh.
51 49 not 50
52 40 and 51
53 (2014* or 2015* or 2016* or 2017* or 2018* or 2019*).ed.
  (Continued)
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54 52 and 53
EMBASE 2017, 2018
and 2019 only
1 exp leg ulcer/
2 exp skin ulcer/
3 ((arter* or foot or leg or lower or mixed) adj3 ulcer*).ti,ab.
4 or/1-3
5 exp biological dressing/
6 exp occlusive dressing/
7 exp hydrogel/
8 exp alginic acid/
9 dressing*.ti,ab.
10 (ActivHeal or Allevyn or Avazorb or Biatain or Copa or LyoFoam or PermaFoam or
PolyMem or Suprasorb or Tegaderm or Tielle or Transobent or Trufoam or UrgoCel-
l).ti,ab.
11 (hydrocolloid* or alginate* or hydrogel*).ti,ab.
12 (foam or bead or film*).ti,ab.
13 (tulle or gauze).ti,ab.
14 (non adj2 adher*).ti,ab.
15 or/1-14
16 exp topical drug administration/
17 exp topical antiinfective agent/
18 exp antiinfective agent/




23 exp growth promotor/
24 exp collagen/
25 or/17-24
26 16 and 25
27 (topical adj2 (steroid* or corticosteroid* or glucocorticoid*)).ti,ab.
28 (topical adj2 (oestrogen or estrogen)).ti,ab.
29 (topical adj2 enzym*).ti,ab.
30 (topical adj2 growth factor*).ti,ab.
31 (topical adj2 collagen).ti,ab.
32 (topical adj2 silver).ti,ab.
2433
  (Continued)
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37 (ointment* or lotion* or cream*).ti,ab.
38 or/27-37
39 15 or 26 or 38
40 4 and 39
41 randomized controlled trial/





47 (compare or compared or comparison).ti.
48 ((evaluated or evaluate or evaluating or assessed or assess) and (compare or
compared or comparing or comparison)).ab.
49 (open adj label).ti,ab.
50 ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab.
51 double blind procedure/
52 parallel group$1.ti,ab.
53 (crossover or cross over).ti,ab.
54 ((assign$ or match or matched or allocation) adj5 (alternate or group$1 or inter-
vention$1 or patient$1 or subject$1 or participant$1)).ti,ab.
55 (assigned or allocated).ti,ab.
56 (controlled adj7 (study or design or trial)).ti,ab.
57 (volunteer or volunteers).ti,ab.
58 trial.ti.
59 or/41-58
60 40 and 59
61 (2017* or 2018* or 2019*).em.
62 60 and 61
63 from 62 keep 2001-2433
CINAHL 2017, 2018
and 2019 only
S55 S53 AND S54
S54 EM 2017 OR EM 2018 OR 2019 EM
501
  (Continued)
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S53 S39 AND S52
S52 S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50
OR S51
S51 MH "Random Assignment"
S50 MH "Single-Blind Studies" or MH "Double-Blind Studies" or MH "Triple-Blind
Studies"
S49 MH "Crossover Design"
S48 MH "Factorial Design"
S47 MH "Placebos"
S46 MH "Clinical Trials"
S45 TX "multi-centre study" OR "multi-center study" OR "multicentre study" OR
"multicenter study" OR "multi-site study"




S40 TX "latin square"
S39 S4 AND S38
S38 S15 OR S25 OR S37
S37 S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36




S32 topical N3 (agent* or preparation* or therap* or treatment*)
S31 topical N2 silver
S30 topical N2 collagen
S29 topical N2 growth factor*
S28 topical N2 enzym*
S27 topical N2 (oestrogen or estrogen)
S26 topical N2 (steroid* or corticosteroid* or glucocorticoid*)
S25 S16 AND S24
S24 S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23
S23 (MH "Collagen")
S22 (MH "Growth Substances+")
S21 (MH "Enzymes+")
  (Continued)
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S20 (MH "Estrogens+")
S19 (MH "Glucocorticoids+")
S18 (MH "Antiinflammatory Agents+")
S17 (MH "Antiinfective Agents, Local+")
S16 (MH "Administration, Topical+")
S15 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR
S13 OR S14
S14 TX non N2 adher*
S13 TX tulle or gauze
S12 TX foam or bead or film*
S11 TX hydrocolloid* or alginate* or hydrogel*
S10 TX ActivHeal or Allevyn or Avazorb or Biatain or Copa or LyoFoam or Per-




S7 (MH "Hydrogel Dressings")
S6 (MH "Occlusive Dressings")
S5 (MH "Biological Dressings")
S4 S1 OR S2 OR S3
S3 TX (arter* or foot or leg or lower or mixed) N3 ulcer*
S2 (MH "Skin Ulcer+")
S1 (MH "Leg Ulcer+")
AMED 2017, 2018 and
2019 only
1 exp Skin Ulcer/
2 ((arter* or foot or leg or lower or mixed) adj3 ulcer*).ti,ab.
3 or/1-2
4 dressing*.ti,ab.
5 (ActivHeal or Allevyn or Avazorb or Biatain or Copa or LyoFoam or PermaFoam or
PolyMem or Suprasorb or Tegaderm or Tielle or Transobent or Trufoam or UrgoCel-
l).ti,ab.
6 (hydrocolloid* or alginate* or hydrogel*).ti,ab.
7 (foam or bead or film*).ti,ab.
8 (tulle or gauze).ti,ab.
9 (non adj2 adher*).ti,ab.
10 or/1-9
11 exp Antiinflammatory agents/
7
  (Continued)
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12 exp Estrogens/
13 exp Enzymes/
14 exp Growth substances/
15 exp Collagen/
16 or/11-15
17 10 and 16
18 (topical adj2 (steroid* or corticosteroid* or glucocorticoid*)).ti,ab.
19 (topical adj2 (oestrogen or estrogen)).ti,ab.
20 (topical adj2 enzym*).ti,ab.
21 (topical adj2 growth factor*).ti,ab.
22 (topical adj2 collagen).ti,ab.
23 (topical adj2 silver).ti,ab.
24 (topical adj3 (agent* or preparation* or therap* or treatment*)).ti,ab.
25 exp Honey/
26 honey.ti,ab.
27 (ointment* or lotion* or cream*).ti,ab.
28 or/18-27
29 10 or 17 or 28
30 3 and 29
31 exp CLINICAL TRIALS/
32 RANDOM ALLOCATION/
33 DOUBLE BLIND METHOD/
34 Clinical trial.pt.
35 (clinic* adj trial*).tw.






42 30 and 41
43 ("2017" or "2018" or "2019").yr.
44 42 and 43
45 from 44 keep 1-7
  (Continued)
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W H A T ' S   N E W
 
Date Event Description
31 May 2019 New search has been performed New search run. One new study included, 19 studies excluded,
two new studies assessed as 'awaiting classification' and four
new ongoing studies identified.
31 May 2019 New citation required but conclusions
have not changed
New search run. One new study included, 19 studies excluded,
two new studies assessed as 'awaiting classification' and four
new ongoing studies identified. New author joined review team.
Text updated to reflect current Cochrane standards. 'Summary of
findings' table added. No change to conclusions.
 
H I S T O R Y
Protocol first published: Issue 4, 1999
Review first published: Issue 1, 2003
 
Date Event Description
16 March 2015 New citation required but conclusions
have not changed
New authors have taken over this review. Searches rerun; no new
studies included, 42 new studies excluded, one previously in-
cluded study now considered excluded. Review updated using
current Cochrane reporting standards including risk of bias. No
change to conclusions
16 March 2015 New search has been performed Searches rerun; no new studies included, 42 new studies exclud-
ed, one previously included study now considered excluded
12 August 2008 Amended Converted to new review format.
10 November 2006 New citation required but conclusions
have not changed
Re-ran searches. New trial added to included studies and new tri-
als added to excluded studies.
 
C O N T R I B U T I O N S   O F   A U T H O R S
CB: evaluated studies for inclusion and exclusion, performed risk of bias, and managed the updating of the review text.
FP: performed risk of bias, and assisted in the updating of the review text, with expert input for the background and discussion of the topic.
RF: managed the updating of the review text.
D E C L A R A T I O N S   O F   I N T E R E S T
CB: none known. CB is employed as Assistant Managing Editor for Cochrane Vascular. Editorial tasks were carried out by other members
of the Cochrane Vascular editorial base
FP: has declared that she received payment for consultancy at the Molnycke Healthcare Key Opinion Leaders Group. This is a wound care
company that supplies dressings, that are used in arterial leg ulcers. She received travel expenses and her institution received payment
for speaking at NHI pressure ulcer session
RF: none known
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S O U R C E S   O F   S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Chief Scientist OFice, Scottish Government Health Directorates, The Scottish Government, UK.
The Cochrane Vascular editorial base is supported by the Chief Scientist OFice
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
2019 update
The original protocol and previous versions of this review planned to report 'economic analysis'. This has now been removed as an outcome
as the team and Cochrane Vascular editorial base do not have the required expertise to present a full economic analysis of interventions.
Any information provided on cost in future updates will be reported in the discussion if appropriate.
2015 update
In the Nelson 2007 version of the review, the authors classified Hartman 2002 as an included study. However, on further investigation into
the trial design, we decided that the control group was not adequate to describe this as an RCT or CCT. We therefore reclassified Hartman
2002 as an excluded study.
In the Types of interventions section, we have added 'compression' interventions as exclusionary criteria as we felt it was an important
distinction to make. Making this alteration did not eFect the inclusion or exclusion of any previously considered studies.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Wound Healing;  Administration, Topical;  Arteries;  Bandages, Hydrocolloid;  Leg Ulcer  [*therapy];  Occlusive Dressings;  Ointments
 [*therapeutic use];  Randomized Controlled Trials as Topic;  Varicose Ulcer  [therapy]
MeSH check words
Humans
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